Peptide LibraryCagrilintide dosage in published studies and labels
These are the doses used for Cagrilintide in FDA labelling and published clinical studies, reported as each source states them, one row per regimen. They describe what was studied or approved for a specific population. They are not a recommendation, and none of them is a dose for any individual.
Research and educational reference only. This is not medical advice, and no figure on this page is a dosing recommendation.
Last checked against primary sources:
Studied regimens and sources
Cagrilintide has no approved dosage. Human dosing comes from Novo Nordisk's registered programme, where 2.4 mg subcutaneously once weekly is the dose carried through phase 3, almost always co-administered with semaglutide 2.4 mg as the fixed combination CagriSema. Most published efficacy is for that combination rather than for cagrilintide alone.
| Human dosing established | Yes |
|---|---|
| Studied dose range | 0.3–4.5 mg once weekly studied; 2.4 mg once weekly carried into phase 3 |
| Route | Subcutaneous |
| Frequency | Once weekly |
| Duration studied | Up to 68 weeks in the phase 3 programme |
| Titration | Stepwise weekly escalation inside the trial protocol, reaching 2.4 mg. |
| Evidence level | Clinical Trial Evidence |
| Last reviewed | 2026-11-07 |
Research-reported dosing
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| Phase 2 dose-finding trial (Lancet 2021)Clinical trial · Randomised, double-blind, placebo- and active-controlled phase 2 trial | Adults without diabetes with obesity, or overweight with hypertension or dyslipidaemia (706 randomised to cagrilintide) | 0.3, 0.6, 1.2, 2.4 or 4.5 mg | Subcutaneous | Once weekly | 26 weeks, including up to 6 weeks of dose escalation | Mean weight change -6.0% to -10.8% across doses vs -3.0% with placebo (trial product estimand) | Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021. |
| REDEFINE 1 — phase 3, coadministered with semaglutideClinical trial · Phase 3 randomised controlled trial | Adults with overweight or obesity | Cagrilintide 2.4 mg with semaglutide 2.4 mg (CagriSema) | Subcutaneous | Once weekly | 68 weeks | Percentage change in body weight | Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2025. |
| REIMAGINE 2 — phase 3, versus semaglutide or cagrilintide aloneClinical trial · Phase 3 double-blind randomised controlled trial | People with type 2 diabetes | Cagrilintide 2.4 mg alone; cagrilintide 2.4 mg with semaglutide 2.4 mg; cagrilintide 1.0 mg with semaglutide 1.0 mg | Subcutaneous | Once weekly | 68 weeks | Glycaemic control and body weight | Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study. Lancet Diabetes Endocrinol. 2026. |
| NCT04982575 — phase 2, results postedClinical trial · Phase 2 trial with posted results | Adults with overweight or obesity (n=92) | Per trial protocol | Subcutaneous | Once weekly | Per trial protocol | Cagrilintide with semaglutide, safety and efficacy | NCT04982575 — Research Study to Look at How Well Cagrilintide Together With Semaglutide Works |
| NCT05669755 — REDEFINE 3, phase 3 cardiovascular outcomesClinical trial · Phase 3 outcomes trial, active not recruiting | Adults with overweight or obesity and cardiovascular disease (n=7101) | Per trial protocol (CagriSema) | Subcutaneous | Once weekly | Per trial protocol | Cardiovascular outcomes | NCT05669755 — REDEFINE 3: A Research Study to See the Effects of CagriSema |
Where sources disagree
- Most phase 3 efficacy attributed to cagrilintide comes from CagriSema, a fixed combination with semaglutide. Weight loss reported for the combination cannot be attributed to cagrilintide alone, and the REIMAGINE 2 design is one of the few that separates them.
- Cagrilintide is not approved by any regulator. Dosing quoted for it is trial dosing, administered under monitoring with protocol-driven escalation.
- Cagrilintide is an amylin analogue, a different mechanism from the GLP-1 and GIP agonists it is usually grouped with. Dosing intuition carried over from semaglutide or tirzepatide does not transfer to it.